PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Настройки учетной записи
    • Выйти
    • Войти
    • Зарегистрироваться

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180202 163717
20180815 142022
20180814 210916
IMG-20170802-WA0013
20180814 165315
20180815 151848
  • Anesthetic and Analgesic Drug Products Advisory Committee Roster
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-04-01 By FDA
  • FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Coronavirus (COVID-19) | CBER-Regulated Biologics
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-31 By FDA
  • Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • We Are Hiring
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Drug Disposal: Questions and Answers
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Guideline on Quality Aspects of Pharmaceutical Veterinary Medicines for administration via drinking water - Draft Annex on compatibility studies between veterinary medicinal products and biocidal products
    Source: EMA - Scientific guidelines (human and veterinary) Published on 2023-03-31
  • Human medicines European public assessment report (EPAR): Dzuveo, sufentanil, Pain, Date of authorisation: 25/06/2018, Revision: 6, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • National Minority Health Month: Better Health Through Better Understanding
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-31 By FDA
  • Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Carcinoma, Renal Cell, Date of authorisation: 25/08/2016, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Identification of Medicinal Products — Implementation and Use
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Newly Added Guidance Documents
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Contraceptives, Oral, Date of authorisation: 19/05/2021, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Neutropenia, Date of authorisation: 20/06/2019, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
Предыдущие записи
Тема: Scaffold от Danny Cooper.